Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Cogent Biosciences Is Maintained at Buy by Needham
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $15
Cogent Biosciences Analyst Ratings
Cogent Biosciences: Buy Rating Affirmed Amid Anticipation for Bezuclastinib Data and Strong Financial Position
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences
Cogent Biosciences Analyst Ratings
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $16
Cogent Biosciences: Promising Pipeline and Strategic Positioning Drive Buy Rating
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $15
Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)
Cogent Biosciences Analyst Ratings
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $13 to $22
Hold Rating on Cogent Biosciences Amid Competitive Landscape and Anticipated Milestones
No Data
No Data